Catalog No.
Product Name
Application
Product Information
Citations
-
α-synuclein/Amyloid-β Aggregation Inhibitor
Scyllo-Inositol is an aggregation inhibitor that targets misfolded proteins, specifically α-synuclein and Amyloid-β. It effectively stabilizes non-toxic oligomers, preventing their conversion into toxic fibrils, thus supporting protein homeostasis and providing neuroprotective effects. By binding to the hydrophobic regions of pathogenic proteins, Scyllo-Inositol inhibits protein aggregation and enhances lysosome- and proteasome-mediated degradation pathways, ultimately reducing neurotoxicity. This compound is valuable for researching neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease. -
Amyloid-β Inhibitor
Hoechst 34580 tetrahydrochloride is a nuclear marker dye that selectively targets A/T-rich double-stranded DNA. This compound exhibits enhanced fluorescence intensity when bound to nucleic acids, making it valuable for live cell labeling applications. As the pH of the solution increases, the fluorescence intensity of Hoechst 34580 also increases, providing a reliable tool for studying cellular dynamics, DNA distribution, and nuclear morphology in real-time. This reagent is particularly useful in research focused on amyloid-β and related neurodegenerative processes. -
Histochemical Stain
X-34 is a lipophilic fluorescent derivative of Congo red, characterized by its bright yellow-green fluorescence. It selectively stains neuritic and diffuse plaques, neurofibrillary tangles, neuropil threads, and cerebrovascular amyloid in brain tissue. This reagent is widely utilized in research focused on Alzheimer's disease to facilitate the study of these key pathological features. -
Peptide
PHF6 (VQIVYK) is a peptide that facilitates the self-assembly and aggregation of the full-length tau protein, specifically targeting the third microtubule-binding repeat region of tau. This peptide is instrumental in studies of tau pathology associated with neurodegenerative diseases, particularly in understanding the mechanisms underlying tau aggregation and its implications in tau-related disorders. Its unique structure makes it a valuable tool for investigating tau fibrillogenesis and potential therapeutic interventions. -
Aβ/tau Aggregation Inhibitor
Aβ/tau aggregation-IN-4 is a potent inhibitor of amyloid-beta (Aβ) and tau aggregation. It effectively promotes the degradation of Aβ40 and Aβ42 with IC50 values of 2.151 μM and 3.622 μM, respectively. Additionally, Aβ/tau aggregation-IN-4 exhibits selective inhibition of acetylcholinesterase (AChE) with an IC50 of 5.56 μM, and inhibits monoamine oxidase A (MAO-A) and B (MAO-B) with IC50 values of 0.59 μM and 0.09 μM, respectively. This compound also reduces intracellular reactive oxygen species (ROS) levels, making it a valuable tool in Alzheimer's disease research. -
GSK3β Inhibitor
GSK3β-IN-3 is an ATP-competitive inhibitor of glycogen synthase kinase 3 beta (GSK3β), exhibiting an IC50 of 0.90 μM. It effectively lowers the phosphorylation levels of tau protein in the BR5706 strain and reduces the accumulation of amyloid-beta (Aβ) aggregates in the CL2006 strain. This compound is essential for research applications focused on Alzheimer's disease (AD), aiding in the understanding of neurodegenerative mechanisms and potential therapeutic strategies. -
hAChE/hBuChE Inhibitor
hAChE-IN-5 is a potent inhibitor of human acetylcholinesterase (hAChE) and human butyrylcholinesterase (hBuChE), exhibiting IC50 values of 0.17 μM for both enzymes. In addition, hAChE-IN-5 demonstrates significant GSK3β inhibition with an IC50 of 0.21 μM. This compound is utilized in research focused on tau protein aggregation and Aβ1-42 self-aggregation, effectively preventing Aβ-dependent neurotoxicity. Furthermore, hAChE-IN-5 can cross the blood-brain barrier, showcasing its potential as a multi-targeted agent in the study of Alzheimer's disease. -
Anti-aggregation Agent
CLR01 sodium is an anti-aggregation agent that effectively penetrates the blood-brain barrier. It inhibits the de novo aggregation of key proteins, including Amyloid-β 40/42, α-synuclein, IAPP, tau protein, and SOD1. CLR01 sodium has demonstrated the ability to reduce amyloid plaque burden in the cortex of triple-transgenic mice, resulting in improvements in memory and motor functions. This compound is applicable in research focused on neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). -
FLNA Modulator
Simufilam hydrochloride is an orally active modulator of filamin A (FLNA) that targets neuronal signaling pathways. This compound restores NMDAR signaling and Arc expression while inhibiting dysregulated mTOR activity. Additionally, it enhances insulin sensitivity and mitigates Aβ42-induced neuroinflammation and tau protein hyperphosphorylation. Simufilam hydrochloride is applicable in research related to Alzheimer's disease, particularly in understanding the underlying mechanisms of neurodegeneration. -
FLNA Modulator
Simufilam is an orally active modulator of filamin A (FLNA) that restores NMDA receptor (NMDAR) signaling and Arc expression. It effectively inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, which results in improved insulin sensitivity and a reduction in Aβ42-induced neuroinflammation and tau protein hyperphosphorylation. This compound is particularly valuable for research applications focused on Alzheimer's disease and related neurodegenerative disorders. -
Neuroprotective Compound
REM127 is a neuroprotective small molecule that modulates calcium homeostasis in cells. It effectively restores calcium balance in cellular models affected by the pathological accumulation of tau protein, demonstrating potential to mitigate synaptic and cognitive deficits in Alzheimer's disease models. REM127 is capable of crossing the blood-brain barrier and may slow the progression of amyloid-beta and tau protein pathologies. This compound is suitable for research applications in neurodegenerative diseases. -
QPCTL Inhibitor
QP5020 is a selective QPCTL inhibitor with an IC50 value of 15 nM. This compound demonstrates notable antitumor efficacy, making it a valuable tool for cancer research. Its mechanism of action provides insights into the role of QPCTL in tumor biology and offers potential avenues for therapeutic exploration. -
Antiamyloid Agent
Squoxin is an antiamyloid agent that specifically targets Aβ1-42, effectively inhibiting its aggregation and fibril formation. This compound is capable of crossing the blood-brain barrier, making it relevant for neurological research. Additionally, Squoxin exhibits anthelmintic activity and possesses anti-inflammatory properties, which further supports its potential applications in various biological and therapeutic studies. -
APP Degrader
Aβ42-IN-4 is an APP degrader that effectively reduces the production of amyloid-β peptide Aβ42 by promoting the degradation of the amyloid precursor protein. This compound is valuable for research applications focused on neurodegenerative diseases, particularly Alzheimer's disease, where the accumulation of Aβ42 is a key pathogenic factor. Its ability to modulate APP levels makes Aβ42-IN-4 a relevant tool for investigating potential therapeutic strategies aimed at reducing amyloid plaque formation. -
Aβ42 Inhibitor
Doliroside A is an Aβ42-binding agent that exhibits an IC50 of 26.57 μM for Aβ42. By binding to Aβ42 nuclei and oligomers, it forms stable complexes that suppress Aβ42 fibrillation, redirecting it into off-pathway, amorphous oligomers. This compound serves as a valuable tool in Alzheimer's disease research, aiding in the understanding of Aβ42 aggregation mechanisms and potential therapeutic strategies. -
BACE1/2 Inhibitor
BACE1/2-IN-1 is a potent dual inhibitor of BACE1 and BACE2, exhibiting IC50 values of 0.01 μM and 0.0053 μM, respectively. This compound demonstrates a favorable pharmacokinetic profile characterized by a lower P-glycoprotein efflux ratio and enhanced passive permeability. In addition, BACE1/2-IN-1 is associated with increased metabolic stability in liver microsomes, making it a valuable tool for researching therapeutic strategies targeting amyloid precursor protein processing in Alzheimer's disease. -
Fusion Protein
Zamubafusp alfa is an immunoglobulin-peptide fusion protein that targets amyloid fibrils and highly sulfated heparan sulfate glycans. This compound enhances macrophage phagocytosis, facilitating the clearance of amyloid deposits. It is particularly relevant for research applications focused on systemic amyloidosis and the development of therapeutic strategies aimed at mitigating amyloid-related diseases. -
BACE1 Inhibitor
2,2′,4,4′-Tetrahydroxychalcone is a selective and potent inhibitor of Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) with an IC50 of 0.62 μM. This compound, derived from Isoliquiritigenin found in Glycyrrhiza uralensis, effectively inhibits the β-cleavage of amyloid precursor protein (APP), leading to a reduction in β-amyloid (Aβ) peptide production. 2,2′,4,4′-Tetrahydroxychalcone is used in research related to Alzheimer's disease, providing insights into potential therapeutic avenues for neurodegenerative conditions. -
Amylin Antagonist
AC 253 is an amylin antagonist that specifically inhibits the binding of 125I-adrenomedullin, demonstrating an IC50 value of 25 nM. This compound is valuable for research applications focused on metabolic disorders and neurodegenerative diseases, where modulation of amylin pathways may play a critical role. -
Aβ Fragment
Amyloid β-Protein (4-42) is a peptide fragment of the amyloid β-protein that is implicated in the pathogenesis of Alzheimer's disease. This Aβ fragment plays a critical role in the aggregation process that forms amyloid plaques, influencing neurotoxicity and synaptic dysfunction. It is commonly used in research focused on neurodegenerative diseases, enabling studies on amyloid aggregation, cell signaling pathways, and potential therapeutic approaches for Alzheimer's disease. -
BACE1 Inhibitor
AZ3971 is a selective BACE1 inhibitor that effectively penetrates the blood-brain barrier, while leaving γ-secretase activity unaffected. By reducing the production of amyloid-beta (Aβ), AZ3971 serves as a valuable tool in the study of Alzheimer's disease and related neurodegenerative disorders. Its oral bioavailability makes it particularly suitable for in vivo research applications. -
Aβ oligomerization Inhibitor
Aβ aggregation-IN-4 is an Aβ oligomerization inhibitor that targets and mitigates the neurotoxicity associated with amyloid-β protein (Aβ). By significantly reducing the formation of oligomeric complexes of Aβ (Aβ-OCs) without affecting total Aβ levels, it effectively attenuates Aβ oligomerization. This compound provides a valuable tool for researching the pathophysiology of Alzheimer's disease (AD) and exploring potential therapeutic strategies. Additionally, Aβ aggregation-IN-4 protects primary cortical neurons from oligomer-induced cell death, highlighting its relevance in neuroprotective studies. -
Tau/Amyloid-β Aggregation Inhibitor
TRV-1387 is a benzofurazan compound that functions as an inhibitor of tau and amyloid-β aggregation. It demonstrates significant biological activity in preventing the formation of toxic aggregates associated with neurodegenerative diseases, making it a valuable tool for research in Alzheimer's disease and related pathologies. TRV-1387 can be utilized to study the mechanisms of amyloid-related toxicity and to explore potential therapeutic strategies targeting protein aggregation. -
Tau/Aβ Inhibitor
D-687 is a selective inhibitor of Tau and amyloid-beta (Aβ) aggregation. It has demonstrated the ability to reverse Aβ1–42-induced neurotoxicity in SH-SY5Y neuronal cells, highlighting its significant neuroprotective effects. This compound is valuable for research focused on Alzheimer's disease and related neurodegenerative disorders. -
QC Inhibitor
Glutaminyl Cyclase Inhibitor 5 is a potent and selective inhibitor of human glutaminyl cyclase (hQC), exhibiting an IC50 value of 3.2 nM. This compound serves as a valuable tool for investigating the role of hQC in neurodegenerative diseases and related biological processes. It is applicable in various research studies focused on glutamate signaling and its implications in disease mechanisms. -
Amyloid-β Precursor
β-Amyloid Protein Precursor 770 (135-155) is a peptide derived from the amyloid precursor protein isoform APP 770, which plays a crucial role in the generation of amyloid-β peptides Aβ40 and Aβ42. This peptide serves as an important tool for studying the mechanisms of amyloidogenic processing and its implications in neurodegenerative diseases such as Alzheimer’s disease. Researchers can utilize this reagent in assays that investigate protein interactions, amyloid formation, and related signaling pathways. -
Tau/Aβ Inhibitor
D-688 is a potent inhibitor of Tau and amyloid-beta (Aβ), demonstrating significant neuroprotective properties. This compound effectively reverses Aβ1–42-induced toxicity in SH-SY5Y neuronal cells, making it a valuable tool for studying neurodegenerative processes. Additionally, D-688 improves the survival rate of Drosophila melanogaster models expressing the human tau protein isoform (2N4R), underscoring its potential in Alzheimer's disease research and related disorders. -
Amyloid-β
LPYFD-NH2 is a pentapeptide that targets the aggregation of amyloid-β (Aβ(1-42)). It demonstrates inhibitory activity against Aβ aggregation, making it a valuable tool for investigating the pathogenic mechanisms underlying Alzheimer’s disease. This compound is suitable for research applications focused on understanding amyloid-related processes in neurodegeneration. -
Anti-Amyloid-β Antibody
Merinetug is a humanized IgG1κ antibody specifically targeting amyloid beta (Aβ). This antibody plays a crucial role in disrupting the aggregation of Aβ, making it valuable for research into Alzheimer’s disease and related neurodegenerative conditions. Merinetug is utilized in various experimental applications, including therapies aimed at modulating amyloid pathology and understanding the mechanisms underlying amyloid-related neurotoxicity. -
Lipid Droplet Formation Inhibitor
Beauveriolide III is a specific inhibitor of lipid droplet formation, effectively reducing lipid accumulation in mouse macrophages. This compound plays a significant role in studies focused on lipid metabolism and its implications in metabolic disorders. Its utility in research can aid in understanding the biological pathways regulating lipid storage and inflammation in macrophage-associated pathologies. -
Amyloid β-Protein (1-40) Fluorescence
5-TAMRA-Amyloid β-Protein (1-40) is a fluorescently labeled peptide targeting the Amyloid β-Protein (1-40) with an excitation/emission wavelength of 544/572 nm. This reagent is designed for the study of amyloid aggregation, facilitating the investigation of Alzheimer's disease pathology. Its fluorescence properties make it suitable for applications in live-cell imaging and fluorescence microscopy, enabling researchers to track amyloid formation and accumulation in various biological contexts. -
AD Molecular Probe
Aftobetin is a non-invasive molecular probe targeting aggregated β-amyloid peptides (Aβ) for the early diagnosis of Alzheimer's disease (AD). This reagent can specifically bind to Aβ aggregates present in the lens of the eye, facilitating rapid and painless detection of AD in patients. Aftobetin serves as a valuable tool in both clinical diagnostics and research applications focused on neurodegenerative disease mechanisms. -
Amyloid-β
SCH 900229 is a selective γ-secretase inhibitor targeting presenilin 1 (PS1) with an Aβ40 IC50 value of 1.3 nM, demonstrating strong efficacy in reducing amyloid-β levels. This compound exhibits significant Aβ-lowering effects following oral administration in preclinical animal models. It has progressed to human clinical trials as a potential therapeutic agent for Alzheimer's disease, highlighting its relevance in neurodegenerative research. -
RAGE/SERT Inhibitor
RAGE/SERT-IN-1 is a potent inhibitor of receptor for advanced glycation end products (RAGE) and serotonin transporter (SERT), demonstrating IC50 values of 8.26 μM and 31.09 nM, respectively. This compound exhibits significant neuroprotective properties against Aβ25-35-induced neuronal damage and has been shown to alleviate depressive behaviors in murine models. RAGE/SERT-IN-1 is a valuable tool for studying the interplay between Alzheimer's disease and depression comorbidity. -
Aβ Aggregation Inhibitor
SEN 304 is an Aβ aggregation inhibitor that directly binds to Aβ(1-42), effectively delaying β-sheet formation while promoting the aggregation of toxic oligomers into a nontoxic form. This compound is primarily utilized in research focused on Alzheimer’s disease, providing insights into the mechanisms of neurodegeneration and potential therapeutic strategies. The ability of SEN 304 to modulate Aβ aggregation makes it a valuable tool for studying amyloid pathology. -
Anti-aggregation Compound
2,3-Dehydrosilybin A is an anti-aggregation compound that targets protein misfolding. This compound exhibits significant potential in preventing amyloid formation and related neurodegenerative disorders. Research applications include studying its impact on cellular longevity and its role in mitigating protein aggregation, making it valuable for exploring therapeutic approaches for age-related diseases. -
Amyloid-β Inhibitor
Aβ Fibrillization Modulator 1 targets amyloid-β (Aβ) by stabilizing Aβ monomers, thus inhibiting the formation of toxic fibrils associated with neurodegenerative diseases. This compound demonstrates potential in research applications focused on Alzheimer's disease and other amyloid-related disorders. By modulating fibrillization, it provides a valuable tool for investigating the mechanisms of amyloid aggregation and the development of therapeutic strategies. -
Aβ42 Inhibitor
2002-G12 is an Aβ42 inhibitor that effectively reduces Aβ42 toxicity by 76%. Its mechanism of action makes it a valuable tool for investigating Alzheimer's disease and studying the role of Aβ42 in neurodegenerative processes. Researchers can utilize 2002-G12 to explore potential therapeutic strategies targeting amyloid-beta aggregation and toxicity. -
Amyloid-β Inhibitor
KMS88009 is a potent amyloid-β oligomer inhibitor that directly disrupts the formation of these aggregates. This compound demonstrates significant potential in preserving cognitive function when administered preventively and reversing cognitive decline therapeutically. In studies using the APP/PS1 double transgenic mouse model, KMS88009 effectively reduced amyloid-β oligomer assembly and improved cognitive performance. Comprehensive evaluations of its physicochemical properties, pharmacokinetics, and toxicity further underscore KMS88009's promise as a therapeutic candidate for Alzheimer's disease. -
Amyloid-β
β-Amyloid (33-40) is a peptide derived from the beta-amyloid protein, encompassing amino acids 33 to 40. This peptide serves as a key target for studies investigating the aggregation processes related to neurodegenerative diseases, particularly Alzheimer’s disease. Its biological activity is critical for understanding amyloid pathology and exploring potential therapeutic strategies in Alzheimer’s research. -
Aβ Fragment
β Amyloid (3-40) is a fragment of amyloid-beta (Aβ) that plays a critical role in Alzheimer's disease pathology. This peptide is involved in the aggregation processes that lead to the formation of amyloid plaques in the brain. Research applications include studies of neurodegeneration, cellular toxicity, and the molecular mechanisms underlying Alzheimer's disease. Its use provides insights into potential therapeutic targets and pathways for intervention in age-related cognitive decline. -
Beta-secretase inhibitor
β-Secretase-IN-5 is a potent inhibitor of beta-secretase, a key enzyme involved in the cleavage of amyloid precursor protein (APP). By selectively reducing the production of amyloid-beta peptides Aβ1-40 and Aβ1-42, this compound is essential for research into Alzheimer's disease mechanisms and therapeutic strategies. Its application in neurodegenerative studies provides valuable insights into potential treatments for Alzheimer's. -
FAM-labeled β-Amyloid (1-40)
β-Amyloid (1-40), FAM-labeled is a fluorescently labeled peptide that targets amyloid plaques associated with Alzheimer's disease. With an excitation wavelength of 492 nm and an emission wavelength of 518 nm, this FAM-tagged β-Amyloid (1-40) enables sensitive detection and visualization of amyloid aggregates in various biological samples. It can be utilized in research applications focused on neurodegenerative disorders, helping to elucidate the pathophysiological role of β-amyloid peptides in Alzheimer's disease progression. -
Aβ Fragment
Amyloid β-Protein (16-22) is a fragment of the amyloid precursor protein, specifically targeting the aggregation processes associated with Alzheimer's disease. This peptide plays a crucial role in the study of amyloid plaque formation and neurotoxicity. Its biological activity is essential for researchers investigating the pathophysiology of Alzheimer's and for developing potential therapeutic strategies to combat amyloid-related disorders. -
Aβ Fragment
β Amyloid (11-42) is a fragment of the amyloid precursor protein, primarily targeting the formation of amyloid plaques in the brain. This peptide plays a crucial role in Alzheimer’s disease research, serving as a key biomarker for studying neurodegeneration and associated pathology. It is widely used in assays to investigate amyloid aggregation and its impact on neuronal function, making it an essential reagent for exploring therapeutic strategies against Alzheimer's disease. -
Aβ Aggregation Inhibitor
SEN-1269 is a potent inhibitor of Aβ aggregation, specifically targeting Aβ(1-42) oligomers. This compound protects neuronal cell lines from the detrimental effects of Aβ(1-42) exposure and mitigates deficits in long-term potentiation (LTP) and memory associated with Aβ oligomer toxicity. SEN-1269 serves as a valuable tool for research investigating the pathophysiology of Alzheimer's disease. -
Tau Imaging Ligand
THK-523 is a selective tau imaging ligand that targets tau pathology associated with neurodegenerative disorders, particularly Alzheimer's disease. Demonstrating high affinity and specificity, THK-523 is effective as an in vivo radiotracer, facilitating the imaging of tau aggregates. Its applications extend to research in tau-related pathologies, aiding in the understanding of tau's role in neurodegeneration and the development of potential therapeutic strategies. -
Amyloid Probe
Chrysamine G is a carboxylic acid analogue of Congo Red, primarily utilized as a probe for detecting amyloid deposition associated with Alzheimer's disease. This compound exhibits significant biological activity by inhibiting Aβ-induced cytotoxicity in PC12 cells, making it a valuable tool in Alzheimer's research and studies focused on amyloid pathology. -
Aβ42 Inhibitor
GL-522, a 4-sulfocalix[8]arene derivative, functions as an Aβ42 inhibitor by engaging in nonspecific and multipoint hydrophobic interactions, exhibiting a Kd of 276 μM. This compound effectively inhibits the fibrillation of Aβ42 and mitigates its cytotoxic effects, making it a valuable tool for research in Alzheimer's disease. Its ability to modulate amyloid aggregation and toxicity positions GL-522 as a significant reagent in neurodegenerative disease studies. -
Aβ Fragment
Amyloid β-Protein (1-46) is a fragment of the amyloid precursor protein that primarily targets amyloid aggregation processes. This peptide is crucial for studying the formation and deposition of amyloid plaques, which are characteristic of Alzheimer's disease pathology. It serves as an important tool for research applications aimed at understanding neurodegenerative mechanisms and testing potential therapeutic agents.
